BBY
49
-3
FITB
65
-3
CMI
60
-4
VZ
62
-2
RHI
30
-3
HPE
71
5
EMC
91
2
VLO
48
-7
PFG
50
-3
EMN
55
2
AIZ
54
-2
PPL
70
-2
CMG
48
-2
KMX
58
6
MAR
72
-5
REGN
50
4
WBA
41
-2
COF
57
-2
GM
82
2
SJM
29
5
BBY
49
-3
FITB
65
-3
CMI
60
-4
VZ
62
-2
RHI
30
-3
HPE
71
5
EMC
91
2
VLO
48
-7
PFG
50
-3
EMN
55
2
AIZ
54
-2
PPL
70
-2
CMG
48
-2
KMX
58
6
MAR
72
-5
REGN
50
4
WBA
41
-2
COF
57
-2
GM
82
2
SJM
29
5
Financhill
Back

PTC Therapeutics 10K Form

Sell
43

PTCT
PTC Therapeutics

Last Price:
$46.95
Seasonality Move:
21.36%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2024-04-25 10Q PTCT/PTC Therapeutics Quarterly
2023-10-26 10Q PTCT/PTC Therapeutics Quarterly
2023-08-03 10Q PTCT/PTC Therapeutics Quarterly
2023-04-27 10Q PTCT/PTC Therapeutics Quarterly
2022-10-27 10Q PTCT/PTC Therapeutics Quarterly
2022-08-04 10Q PTCT/PTC Therapeutics Quarterly

Receive PTCT News And Ratings

See the #1 stock for the next 7 days that we like better than PTCT

PTCT Financial Statistics

Sales & Book Value

Annual Sales: $806.8M
Cash Flow: $867.6M
Price / Cash Flow: 5.51
Annual Sales: $-2.34
Price / Book: 0

Profitability

EPS (TTM): 6.51000
Net Income (TTM): $594.8M
Gross Margin: $749.4M
Return on Equity: 0%
Return on Assets: 30.02%

PTC Therapeutics Earnings Forecast

Key PTC Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 12 years for PTCT is 92.89%.
  • The Selling, General & Administrative Expenses for PTCT have been equal to 37.30% of Gross Profit Margin.
  • The Research & Development expenses have been 66.25% of Revenue.
  • The Net Earning history of PTCT is -45.03% of Total Revenues.
  • Per Share Earnings over the last 14 years have been positive in 5 years.

PTC Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: PTCT
CUSIP: 69366J
Website: ptcbio.com

Debt

Debt-to-Equity Ratio: -1.54
Current Ratio: 3.89
Quick Ratio: 3.76

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

PTCT Technical Analysis vs Fundamental Analysis

Sell
43
PTC Therapeutics (PTCT) is a Sell

Is PTC Therapeutics a Buy or a Sell?

  • PTC Therapeutics stock is rated a Sell
    The current PTC Therapeutics [PTCT] share price is $47.20. The Score for PTCT is 43, which is 14% below its historic median score of 50, and infers higher risk than normal.